Skip to main content

Table 2 Results of clinical trials using MSCs to prevent GVHD

From: Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review

Clinical trial Median age(range) MSC frequency MSC dosage aGVHD morbidity (%) cGVHD morbidity (%) Survival rate (%) Follow-up time References
No.21 Standard prophylaxis group:30y (18–60) Standard prophylaxis + MSCs group:37y (20–63) 1 1 × 106/kg 100d grade II–IV aGVHD:Standard prophylaxis group:29.4 Standard prophylaxis + MSCs group:9.4 p = 0.041 N/A exact time unknown:Standard prophylaxis group:61.8 Standard prophylaxis + MSCs group:81.2 p < 0.05 N/A Kuzmina et al. [42]
No.21 34y (17–63) 1 1.2 (0.9–1.65) × 106/kg 100d grade II–IV aGVHD:Standard prophylaxis group:20.5 Standard prophylaxis + MSCs group:10.2 N/A N/A N/A Shipounova et al. [43]
No.34 MSC group:58y (21–69) historic group:55y (10–69) 1 N/A 100d grade II–IV aGVHD:MSC group:35 historic group:56 grade IV aGVHD:MSC group:10 historic group:19 1y moderate/severe cGVHD:MSC group:65 1y:MSC group:80 historic group:44 p = 0.02 560d Baron et al. [93]
No.38 MSC group:6.9y (3.3–12.5) historic group:9.5y (8.4–18.7) 1 1/5 × 106/kg grade I–II aGVHD:MSC group:57.1 historic group:62.5 p = 0.83 grade III–IV aGVHD:MSC group:14.3 historic group:0 p = 0.36 extensive cGVHD:MSC group:14.3 historic group:50.0 p = 0.27 2y:MSC group:85.7 historic group:55.6 p = 0.15 N/A Lee et al. [94]
No.60 N/A 3.7 (2–4) 3 × 107/100 mL/m N/A 2y:MSC group:27.4 control group:49.0 p = 0.021 2y:MSC group:66.1 historic group:61.3 p > 0.05 51m Gao et al. [92]
  1. d represents days; w represents weeks; y represents years